Testosterone deficiency in non-cancer opioid-treated patients
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Purpose: The use of opioids in patients with chronic non-cancer pain is common and can be associated with opioid-induced androgen deficiency (OPIAD) in men. This review aims to evaluate the current literature regarding the prevalence, clinical consequence and management of OPIAD. Methods: A database search was performed in Medline, Embase and Cochrane using terms such as “analgesics”, “opioids” and “testosterone”. Relevant literature from January 1969 to March 2018 was evaluated. Results: The prevalence of patients with OPIAD ranges from 19 to 86%, depending on the criteria for diagnosis of hypogonadism. The opioid-induced suppression of gonadotropin-releasing and luteinizing hormones represents the main important pathogenetic mechanisms. OPIAD has significant negative clinical consequences on sexual function, mood, bone density and body composition. In addition, OPIAD can also impair pain control leading to hyperalgesia, which can contribute to sexual dysfunction and mood impairment. Conclusions: OPIAD is a common adverse effect of opioid treatment and contributes to sexual dysfunction, impairs pain relief and reduces overall quality of life. The evaluation of serum testosterone levels should be considered in male chronic opioid users and the decision to initiate testosterone treatment should be based on the clinical profile of individuals, in consultation with the patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
Endocrine consequences of long-term intrathecal administration of opioids
Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J.-P., Opsomer, F., Adriaensen, H., Verlooy, J., Van Havenbergh, T., Smet, M., & Van Acker, K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6615 · Cited by 491
Hypogonadism in men consuming sustained-action oral opioids
Daniell, H. W. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.126790 · Cited by 401
Lipid solubility and drug penetration of the blood brain barrier
Oldendorf, W. H. (1974) · Experimental Biology and Medicine · doi:10.3181/00379727-147-38444 · Cited by 373
Kennedy, J., Roll, J. M., Schraudner, T., Murphy, S., & McPherson, S. (2014) · The Journal of Pain · doi:10.1016/j.jpain.2014.05.009 · Cited by 292
Testosterone supplementation and sexual function: A meta-analysis study
Corona, G., Isidori, A. M., Buvat, J., Aversa, A., Rastrelli, G., Hackett, G., Rochira, V., Sforza, A., Lenzi, A., Mannucci, E., et al. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12536 · Cited by 263
Self-citationBliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., & Klingmüller, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0929 · Cited by 236
Research works printed but not linked: 109
- Phillips CJ (2009) The cost and burden of chronic pain. Rev Pain 3(1):2–5 · DOI · Paper page
- Coluzzi F (2017) “I am in pain”: is it really the magic formula to open the door of opioid abuse? Minerva Anestesiol 83(12):1332–1333 · DOI
- Kress HG, Ahlbeck K, Aldington D et al (2014) Managing chronic pain in elderly patients requires a change of approach. Curr Med Res Opin 30(6):1153–1164 · DOI
- Ambrosio F, Finco G, Mattia C et al (2006) SIAARTI chronic non-cancer pain study group. Minerva Anestesiol 72:80–859
- Chou R, Fanciullo GJ, Fine PG et al (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10(2):113–30. e22 · DOI · Paper page
- Manchikanti L, Abdi S, Atluri S et al (2012) American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2–guidance. Pain Phys 15(3 Suppl):S67–S116
- Mattia C, Di Bussolo E, Coluzzi F (2012) Non-analgesic effects of opioids: the interaction of opioids with bone and joints. Curr Pharm Des 18(37):6005–6009 · DOI
- Coluzzi F, Rocco A, Mandatori I et al (2012) Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation. Curr Pharm Design. 18(37):6043–6052 · DOI
- Kumar L, Barker C, Emmanuel A (2014) Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroent Res Pract 2014:141737 · DOI
- Corona G, Vignozzi L, Sforza A et al (2013) Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Men’s Health 31(2):103–125 · DOI
- Corona G, Maseroli E, Rastrelli G et al (2016) Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol 41(2):196–210
- Brennan MJ (2013) The effect of opioid therapy on endocrine function. Am J Med 126(3):S12–S18 · DOI
- Aloisi AM, Aurilio C, Bachiocco V et al (2009) Endocrine consequences of opioid therapy. Psychoneuroendocrino 34(Suppl 1):S162–S168 · DOI · Paper page
- Smith HS, Elliott JA (2012) Opioid-induced androgen deficiency (OPIAD). Pain Phys 15(3 Suppl):145–156
- Grossmann M, Matsumoto AM (2017) A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocr Metab 102(3):1067–1075 · DOI · Paper page
- Pathan H, Williams J (2012) Basic opioid pharmacology: an update. Br J Pain 6(1):11–16 · DOI · Paper page
- Stein C, Schäfer M, Machelska H (2003) Attacking pain at its source: new perspectives on opioids. Nat Med 9(8):1003 · DOI · Paper page
- Corbett AD, Henderson G, McKnight AT et al (2006) 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 147(S1):S153–S162 · DOI · Paper page
- Schwarzer C (2009) 30 years of dynorphins—new insights on their functions in neuropsychiatric diseases. Pharmacol Ther 123(3):353–370 · DOI · Paper page
- McDonald J, Lambert D (2005) Opioid receptors. Contin Educ Anaesth Crit Care Pain 5(1):22–25 · DOI
- Coluzzi F, Taylor R Jr, Pergolizzi JV Jr et al (2016) Good clinical practice guide for opioids in pain management: the three Ts—titration (trial), tweaking (tailoring), transition (tapering). Braz J Anesthesiol 66(3):310–317 · DOI
- Daubresse M, Chang HY, Yu Y et al (2013) Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. Med Care 51(10):870–878 · DOI · Paper page
- Lurcott G (1998) The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone. Anesth Prog 45(4):154
- Mattia C, Coluzzi F (2015) A look inside the association codeine-paracetamol: clinical pharmacology supports analgesic efficacy. Eur Rev Med Pharmacol Sci 19(3):507–516
- Dayer P, Collart L, Desmeules J (1994) The pharmacology of tramadol. Drugs 47(1):3–7 · DOI · Paper page
- Mattia C, Coluzzi F (2005) Tramadol. Focus on musculoskeletal and neuropathic pain. Minerva Anestesiol 71(10):565–584
- Mattia C, Coluzzi F (2006) Once-daily tramadol in rheumatological pain. Expert Opin Pharmacother 7(13):1811–1823 · DOI
- Coluzzi F, Mattia C (2007) Chronic non-cancer pain: focus on once-daily tramadol formulations. Ther Clin Risk Manag 3(5):819–829
- Mattia C, Coluzzi F, Sarzi Puttini P et al (2008) Paracetamol/Tramadol association: the easy solution for mild-moderate pain. Minerva Med 99(4):369–390
- Trescot AM, Datta S, Lee M et al (2008) Opioid pharmacology. Pain Physician 11(2 Suppl):S133–S153 · DOI · Paper page
- Ghelardini C, Mannelli LDC, Bianchi E (2015) The pharmacological basis of opioids. Clin Cases Miner Bone Metabol 12(3):219
- Coluzzi F, Mattia C (2005) Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol 71(7–8):451–460
- Nielsen CK, Ross FB, Lotfipour S et al (2007) Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 132(3):289–300 · DOI · Paper page
- Kim ES (2017) Oxycodone/naloxone prolonged release: a review in severe chronic pain. Clin Drug Investig 37(12):1191–1201 · DOI
- Baron R, Jansen JP, Binder A et al (2016) Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. Pain Pract 16(5):600–619 · DOI
- Coluzzi F, Mattia C (2010) OROS(R) hydromorphone in chronic pain management: when drug delivery technology matches clinical needs. Minerva Anestesiol 76(12):1072–1084
- Scholz J, Steinfath M, Schulz M (1996) Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. Clin Pharmacokinet 31(4):275–292 · DOI · Paper page
- Kornick CA, Santiago-Palma J, Moryl N et al (2003) Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 26(13):951–973 · DOI
- Rubinstein AL, Carpenter DM (2017) Association between commonly prescribed opioids and androgen deficiency in men: a retrospective cohort analysis. Pain Med 18(4):637–644 · DOI · Paper page
- Coluzzi F, Fornasari D, Pergolizzi J et al (2017) From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur Rev Med Pharmacol Sci 21(7):1672–1683
- Pergolizzi JV Jr, Breve F, Taylor R Jr et al (2017) Considering tapentadol as a first-line analgesic: 14 questions. Pain Manag 7(4):331–339 · doi:10.2217/pmt-2016-0063
- Billeci D, Coluzzi F (2017) Tapentadol extended release for the management of chronic neck pain. J Pain Res 10:495–505 · DOI
- Pergolizzi JV Jr, Taylor R Jr, LeQuang JA et al (2018) Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain. Pain Ther 7:37–57 · DOI
- Vadivelu N, Kai A, Maslin B et al (2015) Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Ther Clin Risk Manag 11:95–105 · DOI · Paper page
- Coluzzi F, Ruggeri M (2014) Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin 30(6):1139–1151 · DOI
- Ide S, Minami M, Satoh M et al (2004) Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in μ-opioid receptor knockout mice. Neuropsychopharmacology 29(9):1656 · DOI
- Pergolizzi JV, Coluzzi F, Taylor R (2018) Transdermal buprenorphine for moderate chronic noncancer pain syndromes. Expert Rev Neurother 18(5):359–369 · DOI
- Coluzzi F, Bifulco F, Cuomo A et al (2017) The challenge of perioperative pain management in opioid-tolerant patients. Ther Clin Risk Manag 13:1163–1173 · DOI
- Azizi F, Vagenakis AG, Longcope C et al (1973) Decreased serum testosterone concentration in male heroin and methadone addicts. Steroids 22(4):467–472 · DOI
- Cicero TJ, Bell RD, Wiest WG et al (1975) Function of the male sex organs in heroin and methadone users. N Engl J Med 292(17):882–887 · DOI · Paper page
- Drobnis EZ, Nangia AK (2017) Antivirals and male reproduction. Adv Exp Med Biol 1034:163–178 · doi:10.1007/978-3-319-69535-8_11
- Roberts LJ, Finch PM, Pullan PT et al (2002) Sex hormone suppression by intrathecal opioids: a prospective study. Clin J Pain 18(3):144–148 · DOI · Paper page
- Rajagopal A, Vassilopoulou-Sellin R, Palmer JL et al (2003) Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manag 26(5):1055–1061 · DOI
- Dudley U, Duarte RV (2013) Prevalence and influence of diagnostic criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. Pain Physician 16:9–14
- Rubinstein AL, Carpenter DM, Minkoff JR (2013) Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids. Clin J Pain 29(10):840–845 · DOI · Paper page
- Ajo R, Segura A, Inda MM et al (2016) Opioids increase sexual dysfunction in patients with non-cancer pain. J Sex Med 13(9):1377–1386 · DOI
- Cepeda MS, Zhu V, Vorsanger G et al (2015) Effect of opioids on testosterone levels: cross-sectional study using NHANES. Pain Med 16(12):2235–2242 · DOI
- Kim CH, Garcia R, Stover J et al (2014) Androgen deficiency in long-term intrathecal opioid administration. Pain Physician 17(4):543–548 · DOI
- Elliott JA, Horton E, Fibuch EE (2011) The endocrine effects of long-term oral opioid therapy: a case report and review of the literature. J Opioid Manag 7(2):145–154 · DOI · Paper page
- Eichenbaum G, Gohler K, Etropolski M et al (2015) Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency. J Opioid Manag 11(3):211–227 · DOI
- Corona G, Giagulli VA, Maseroli E et al (2016) Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest 39(9):967–981 · DOI · Paper page
- Corona G, Giorda C, Cucinotta D et al (2013) The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. J Endocrinol Invest 36(10):864–868
- Kelly D, Jones T (2015) Testosterone and obesity. Obes Rev 16(7):581–606 · DOI · Paper page
- Wiesner J, Koenig J, Krulich L et al (1984) Site of action for β-endorphin-induced changes in plasma luteinizing hormone and prolactin in the ovariectomized rat. Life Sci 34(15):1463–1473 · DOI
- Li S, Pelletier G (1993) Opioid regulation of gonadotropin-releasing hormone gene expression in the male rat brain as studied by in situ hybridization. NeuroReport 4(3):331–333 · DOI
- Gabriel SM, Simpkins JW, Kalra SP et al (1985) Chronic morphine treatment induces hypersensitivity to testosterone-negative feedback in castrated male rats. Neuroendocrinology 40(1):39–44 · DOI
- Aloisi AM, Ceccarelli I, Fiorenzani P et al (2010) Aromatase and 5-alpha reductase gene expression: modulation by pain and morphine treatment in male rats. Mol Pain 6(1):69
- Rosa M, de la Raymond E, Hennessey M, James V (1996) Hypogonadism and methadone: hypothalamic hypogonadism after long-term use of high-dose methadone. Endocr Pract 2(1):4–7 · DOI
- Petraglia F, Bernasconi S, Iughetti L et al (1986) Naloxone-induced luteinizing hormone secretion in normal, precocious, and delayed puberty. J Clin Endocrinol Metab 63(5):1112–1116 · DOI
- Vermeulen A, Deslypere JP, Kaufman JM (1989) Influence of antiopioids on luteinizing hormone pulsatility in aging men. J Clin Endocrinol Metab 68(1):68–72 · DOI · Paper page
- Rastrelli G, Giovannini L, Calogero A et al (2016) Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry. J Endocrinol Invest 39(6):695–708 · DOI
- Corona G, Bianchini S, Sforza A et al (2015) Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men. Hormones (Athens) 14(4):569–578 · DOI
- Maseroli E, Corona G, Rastrelli G et al (2015) Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med 12(4):956–965 · DOI · Paper page
- Lamm S, Chidakel A, Bansal R (2016) Obesity and hypogonadism. Urol Clin 43(2):239–245 · DOI
- Isidori AM, Balercia G, Calogero A et al (2015) Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest 38(1):103–112 · DOI · Paper page
- Lee KS, Zhang Y, Asgar J et al (2016) Androgen receptor transcriptionally regulates μ-opioid receptor expression in rat trigeminal ganglia. Neuroscience 331:52–61 · DOI
- Corona G, Isidori AM, Aversa A et al (2016) Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med 13(3):317–337 · DOI · Paper page
- Ambler N, de Williams AC, Hill P et al (2001) Sexual difficulties of chronic pain patients. Clin J Pain 17(2):138–145 · DOI · Paper page
- Tajar A, O’Neill TW, Lee DM et al (2011) The effect of musculoskeletal pain on sexual function in middle-aged and elderly European men: results from the European male ageing study. J Rheumatol 38(2):370–377 · DOI
- Carosa E, Benvenga S, Trimarchi F et al (2002) Sexual inactivity results in reversible reduction of LH bioavailability. Int J Impot Res 14(2):93–99 (Discussion 100) · DOI
- Carosa E, Martini P, Brandetti F et al (2004) Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol 61(3):382–386 · DOI
- Fabbri A, Jannini EA, Gnessi L et al (1989) Neuroendocrine control of male reproductive function. The opioid system as a model of control at multiple sites. J Steroid Biochem 32(1B):145–150 · DOI
- Fabbri A, Jannini EA, Ulisse S et al (1988) Low serum bioactive luteinizing hormone in nonorganic male impotence: possible relationship with altered gonadotropin-releasing hormone pulsatility. J Clin Endocrinol Metab 67(5):867–875 · DOI
- Fabbri A, Jannini EA, Gnessi L et al (1989) Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology 14(1–2):103–111 · DOI
- Deyo RA, Smith DH, Johnson ES et al (2013) Prescription opioids for back pain and use of medications for erectile dysfunction. Spine 38(11):909 · DOI
- Davis MP, Mehta Z (2016) Opioids and chronic pain: where is the balance? Curr Oncol Rep 18(12):71 · DOI
- Smith K, Mattick RP, Bruno R et al (2015) Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain. J Affect Disord 184:72–80 · DOI
- Smith JB, Rosen J, Colbert A (2018) Low serum testosterone in outpatient psychiatry clinics: addressing challenges to the screening and treatment of hypogonadism. Sex Med Rev 6(1):69–76 · DOI
- Rastrelli G, Maggi M, Corona G (2018) Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol 11:439–458 · DOI · Paper page
- Rochira V, Antonio L, Vanderschueren D (2018) EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology 6(2):272–285 · DOI · Paper page
- Vestergaard P, Rejnmark L, Mosekilde L (2006) Fracture risk associated with the use of morphine and opiates. J Intern Med 260(1):76–87 · DOI · Paper page
- Saunders KW, Dunn KM, Merrill JO et al (2010) Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med 25(4):310–315 · DOI · Paper page
- Højsted J, Ekholm O, Kurita GP et al (2013) Addictive behaviors related to opioid use for chronic pain: a population-based study. Pain 154(12):2677–2683 · DOI
- Birke H, Kurita G, Sjøgren P et al (2016) Chronic non-cancer pain and the epidemic prescription of opioids in the Danish population: trends from 2000 to 2013. Acta Anaesth Scand 60(5):623–633 · DOI · Paper page
- Nogueiras R, Romero-Picó A, Vazquez MJ et al (2012) The opioid system and food intake: homeostatic and hedonic mechanisms. Obes Facts 5(2):196–207 · DOI
- Corona G, Maseroli E, Maggi M (2014) Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacol 15(13):1903–1926 · DOI · Paper page
- Francomano D, Bruzziches R, Barbaro G et al (2014) Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 37(4):401–411 · DOI
- Corona G, Sforza A, Maggi M (2017) Testosterone replacement therapy: long-term safety and efficacy. World J Mens Health 35(2):65–76 · DOI · Paper page
- Corona G, Dicuio M, Rastrelli G et al (2017) Testosterone treatment and cardiovascular and venous thromboembolism risk: what is ‘new’? J Invest Med 65:964–973 · DOI · Paper page
- Anawalt BD, Yeap BB (2018) Conclusions about testosterone therapy and cardiovascular risk. Asian J Androl 20(2):152 · DOI
- Corona G, Rastrelli G, Maseroli E et al (2014) Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology 2(5):741–747 · DOI
- Corona G, Rastrelli G, Monami M et al (2011) Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction. J Sex Med 8(7):2098–2105 · DOI · Paper page
- Li L, Setoguchi S, Cabral H et al (2013) Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med 273(5):511–526 · DOI · Paper page
- Mendelson JH, Mendelson JE, Patch VD (1975) Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther 192(1):211–217 · DOI · Paper page
- Basaria S, Travison TG, Alford D et al (2015) Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain 156(2):280–288 · DOI · Paper page
- Blick G, Khera M, Bhattacharya RK et al (2012) Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med 13(5):688–698 · DOI · Paper page
- Corona G, Rastrelli G, Morgentaler A et al (2017) Meta-analysis of results of testosterone therapy on sexual function based on International Index of Erectile Function Scores. Eur Urol 72(6):1000–1011 · DOI · Paper page
- Corona G, Ratrelli G, Maggi M (2015) The pharmacotherapy of male hypogonadism besides androgens. Expert Opin Pharmacol 16(3):369–387 · DOI · Paper page
- Corona G, Rastrelli G, Reisman Y et al (2018) The safety of available treatments of male hypogonadism in organic and functional hypogonadism. Expert Opin Drug Saf 17:277–292 · DOI
Cited by
Corona, G., Goulis, D. G., Huhtaniemi, I., Zitzmann, M., Toppari, J., Forti, G., Vanderschueren, D., & Wu, F. C. (2020) · Andrology · doi:10.1111/andr.12770 · Cited by 431
Self-citationOpioids and their endocrine effects: a systematic review and meta-analysis
de Vries, F., Bruin, M., Lobatto, D. J., Dekkers, O. M., Schoones, J. W., van Furth, W. R., Pereira, A. M., Karavitaki, N., Biermasz, N. R., & Zamanipoor Najafabadi, A. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz022 · Cited by 139
Treatment of Functional Hypogonadism Besides Pharmacological Substitution
Corona, G., Rastrelli, G., Morelli, A., Sarchielli, E., Cipriani, S., Vignozzi, L., & Maggi, M. (2020) · The World Journal of Men's Health · doi:10.5534/wjmh.190061 · Cited by 87
Self-citationOpioid-induced endocrinopathies
Fountas, A., Van Uum, S., & Karavitaki, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30254-2 · Cited by 77
The effect of opiates on bone formation and bone healing
Coluzzi, F., Scerpa, M. S., & Centanni, M. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00585-4 · Cited by 55
Self-citation
Metadata
- Authors
- Coluzzi, F., Billeci, D., Maggi, M., & Corona, G.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2018-10-20
- Volume
- 41
- Issue
- 12
- Pages
- 1377-1388
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W2897436693
- Cited by
- 81
- References
- 28
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Testosterone deficiency in non-cancer opioid-treated patients. https://app.cochat.ai/papers/10.1007/s40618-018-0964-3
- The paper
- Coluzzi, F., Billeci, D., Maggi, M., & Corona, G. (2018). Testosterone deficiency in non-cancer opioid-treated patients. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-018-0964-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.